Anuh Pharma Limited (IN:ANUHPHR)
:ANUHPHR
Top Page
Anuh Pharma Limited
(ANUHPHR)
Select Model
Select Model
Rating:62Neutral
Price Target:
₹71.00
▼(-8.42% Downside)
Action:ReiteratedDate:12/18/25
Anuh Pharma Limited's overall stock score reflects solid financial health with consistent revenue growth and a strong balance sheet. However, the stock is currently in a bearish trend, trading below key moving averages. The valuation is fair, with a reasonable P/E ratio and moderate dividend yield. The absence of earnings call data and corporate events limits additional insights.
Positive Factors
Low leverage / strong balance sheet
A very low debt-to-equity ratio and strong equity base give the company durable financial flexibility. This reduces bankruptcy risk, supports investment or M&A funding without equity dilution, and sustains operations through industry cycles for 2–6+ months and beyond.
Negative Factors
Declining net margins and ROE
Falling net margins and a meaningful drop in ROE signal pressure on profitability and returns on shareholder capital. If structural, margin erosion reduces retained earnings and investment capacity, weakening long-term growth prospects and return targets for investors.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
A very low debt-to-equity ratio and strong equity base give the company durable financial flexibility. This reduces bankruptcy risk, supports investment or M&A funding without equity dilution, and sustains operations through industry cycles for 2–6+ months and beyond.
Read all positive factors
Anuh Pharma Limited (ANUHPHR) vs. iShares MSCI India ETF (INDA)
Market Cap
₹7.94B
Dividend Yield1.92%
Average Volume (3M)6.00K
Price to Earnings (P/E)15.0
Beta (1Y)0.61
Revenue Growth14.09%
EPS Growth-34.41%
CountryIN
Employees295
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.34
Shares Outstanding100,224,000
10 Day Avg. Volume6,374
30 Day Avg. Volume5,996
Financial Highlights & Ratios
PEG Ratio-0.77
Price to Book (P/B)2.36
Price to Sales (P/S)1.17
P/FCF Ratio45.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Anuh Pharma Limited Business Overview & Revenue Model
Company Description
Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-bacterial, anti-asthmatics, anti-diabetics, intermediates, expectorant, ...
How the Company Makes Money
Anuh Pharma primarily makes money by selling active pharmaceutical ingredients (APIs)/bulk drugs to pharmaceutical companies that use these inputs to manufacture finished dosage formulations (such as tablets, capsules, and injectables). Revenue is...
Anuh Pharma Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.84B | 6.62B | 6.47B | 5.27B | 4.87B |
| Gross Profit | 910.30M | 1.62B | 1.60B | 1.26B | 1.09B |
| EBITDA | 329.27M | 703.64M | 872.47M | 573.89M | 520.43M |
| Net Income | 200.69M | 473.52M | 600.58M | 361.80M | 305.61M |
Balance Sheet | |||||
| Total Assets | 5.09B | 5.07B | 4.46B | 4.05B | 3.47B |
| Cash, Cash Equivalents and Short-Term Investments | 135.33M | 734.15M | 622.56M | 530.77M | 252.65M |
| Total Debt | 2.27M | 108.86M | 26.93M | 9.07M | 42.23M |
| Total Liabilities | 1.82B | 1.81B | 1.54B | 1.64B | 1.33B |
| Stockholders Equity | 3.27B | 3.26B | 2.91B | 2.41B | 2.14B |
Cash Flow | |||||
| Free Cash Flow | -58.52M | 169.79M | 79.08M | 523.51M | 272.49M |
| Operating Cash Flow | 121.88M | 371.25M | 129.25M | 539.02M | 288.64M |
| Investing Cash Flow | 162.28M | -199.09M | 9.18M | -434.84M | -78.17M |
| Financing Cash Flow | -294.46M | -48.60M | -85.68M | -122.87M | -194.49M |
Anuh Pharma Limited Technical Analysis
Positive
77.53
Price Trends
76.42
Positive
77.32
Positive
84.10
Negative
Market Momentum
-0.16
Negative
60.67
Neutral
91.47
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ANUHPHR, the sentiment is Positive. The current price of 77.53 is above the 20-day moving average (MA) of 74.46, above the 50-day MA of 76.42, and below the 200-day MA of 84.10, indicating a neutral trend. The MACD of -0.16 indicates Negative momentum. The RSI at 60.67 is Neutral, neither overbought nor oversold. The STOCH value of 91.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ANUHPHR.
Anuh Pharma Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹11.54B | 8.47 | ― | 0.37% | ― | ― | |
64 Neutral | ₹7.59B | 19.44 | ― | 1.96% | -6.96% | -66.75% | |
64 Neutral | ₹8.40B | 12.53 | ― | ― | 8.92% | -5.56% | |
62 Neutral | ₹7.94B | 14.99 | ― | 1.92% | 14.09% | -34.41% | |
60 Neutral | ₹7.70B | 22.95 | ― | 0.48% | -18.86% | -150.92% | |
56 Neutral | ₹4.49B | 34.53 | ― | ― | 32.95% | 67.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:ANUHPHR
Anuh Pharma Limited
79.24
-6.34
-7.41%
IN:KILITCH
Kilitch Drugs (India) Limited
128.35
-33.83
-20.86%
IN:KOPRAN
Kopran Limited
157.10
-38.94
-19.86%
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
576.10
13.96
2.48%
IN:THEMISMED
Themis Medicare Limited
83.56
-45.81
-35.41%
IN:WANBURY
Wanbury Limited
240.45
-15.50
-6.06%
Anuh Pharma Limited Corporate Events
Anuh Pharma Publishes Q3 FY26 Unaudited Results in Newspapers and Online
Feb 8, 2026
Anuh Pharma Limited has notified the stock exchanges that its unaudited financial results for the quarter ended 31 December 2025 have been published in leading English and Marathi newspapers. The company has also provided a QR code and webpage det...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.